Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.55 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.48 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.48 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18095095 | 0.86 | GPR84 (0.55) | GPR84NPC1KDM4EALDH1A1HPGD | |
| SCHEMBL13386773 | 0.85 | ALDH1A1 (0.60) | PFKFB2PFKFB1PFKFB3NPC1KDM4E | |
| SCHEMBL1646960 | 0.83 | KDM4E (0.48) | GPR84PFKFB2PFKFB1PFKFB3KDM4E | |
| SCHEMBL18984453 | 0.82 | HTR7 (0.52) | PFKFB2PFKFB1PFKFB3KDM4EALDH1A1 | |
| SCHEMBL1647066 | 0.80 | NR4A2 (0.42) | GPR84PFKFB2PFKFB1PFKFB3ALDH1A1 | |
| SCHEMBL2999443 | 0.80 | GPR84 (0.65) | GPR84NPC1HTR7HTR6MEN1 | |
| SCHEMBL27365216 | 0.79 | NR4A2 (0.72) | GPR84NPC1KDM4EALDH1A1HPGD | |
| SCHEMBL14120820 | 0.79 | GPR84 (0.60) | GPR84NPC1KDM4EALDH1A1HPGD | |
| SCHEMBL188311 | 0.78 | IMPDH2 (0.52) | GPR84PFKFB2PFKFB1PFKFB3NPC1 | |
| SCHEMBL3388496 | 0.78 | GPR84 (0.59) | GPR84NPC1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3925956-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115490751-A | Factor D inhibitors | 拜奥克里斯特制药公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-109121414-B | Benzopyrazole compounds and analogs thereof | 拜奥克里斯特制药公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3411411-B3 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3411411-B3 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3411411-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | Biocryst Pharmaceuticals, Inc. (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017136395-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136395-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| EP-1170009-B1 | Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-0880519-B1 | THIAZOLYLBENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-1170009-A2 | Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-5994378-A | ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| CN-1209809-A | Noval chemical compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-03-03 | — | — | CN | disclosed |
| EP-0880519-A1 | THIAZOLYLBENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997027190-A1 | THIAZOLYLBENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | GPR84 4602/4885PFKFB2 1204/4885PFKFB1 1031/4885 |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | GPR84 4091/4885PFKFB2 1327/4885PFKFB1 1028/4885 |
| US-11559515-B2 | Indole compounds and analogues thereof | C5, IDO1, IDO2 | GPR84 3067/4885PFKFB2 3240/4885PFKFB1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.